Read by QxMD icon Read


(no author information available yet)
Inhaled corticosteroids such as beclometasone are the drugs of choice for long-term treatment of patients with persistent asthma. There is no tangible difference in efficacy among inhaled corticosteroids, but we have the most experience with beclometasone. Ciclesonide (Alvesco, Nycomed then Takeda), another inhaled cortico-steroid, has been tested in three double-blind trials versus budesonide and six trials versus fluticasone but none versus beclometasone. These trials showed the "non-inferiority" of ciclesonide, mainly in terms of a surrogate endpoint: the change in forced expiratory volume in one second (FEV1) after 12 or 24 weeks of treatment (primary endpoint)...
September 2013: Prescrire International
Rüdiger Nave
Ciclesonide (Alvesco(®)) is an inhaled corticosteroid administered as a solution via a metered-dose inhaler, using hydrofluoroalkane HFA-134a as a propellant. Ciclesonide is inhaled as a prodrug, which is activated by pulmonary esterases to the pharmacologically active metabolite desisobutyryl-ciclesonide (des-CIC). Lung deposition is an important factor that contributes to the desired therapeutic effect of inhaled corticosteroid. More than 50% of the inhaled dose is deposited in the lung as demonstrated by scintigraphical methods after inhalation of ciclesonide...
April 2010: Bioanalysis
Gary Laustsen, Fernando Carrillo, Jessica Johnson, Cynthia Smith
No abstract text is available yet for this article.
February 2009: Nurse Practitioner
Takashi Nonaka, Yasuhiro Katsuura, Hiroyuki Sugiyama, Fuminori Miyagi
No abstract text is available yet for this article.
October 2008: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
(no author information available yet)
No abstract text is available yet for this article.
September 22, 2008: Medical Letter on Drugs and Therapeutics
Emma D Deeks, Caroline M Perry
Ciclesonide (Alvesco) is an inhaled corticosteroid used in the preventative treatment of persistent bronchial asthma in adults, adolescents and, in some countries, children. The drug is delivered by a non-chlorofluorocarbon hydrofluoroalkane (HFA) metered-dose inhaler (MDI). In the lungs, ciclesonide is converted to an active metabolite, which is responsible for the beneficial effects of the drug in patients with asthma. Ciclesonide and its active metabolite have low systemic bioavailability and therefore have a low potential to produce systemic adverse events...
2008: Drugs
Gary Laustsen
No abstract text is available yet for this article.
July 2008: Nurse Practitioner
(no author information available yet)
Inhaled corticosteroid therapy is an important part of asthma management.1 In England last year, over 8.4 million prescriptions for an inhaled corticosteroid (not including combination products) were dispensed in the community, at a total net cost to the NHS of around pound138 million.2 Most of these prescriptions were for beclometasone dipropionate (79% of items, pound81million); fluticasone propionate and budesonide accounted for 11% (pound30 million) and 9% (pound25 million), respectively. Around 0.3% of items were for ciclesonide (Alvesco-Altana Pharma), a newer inhaled corticosteroid...
November 2007: Drug and Therapeutics Bulletin
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"